DART Study A phase 2 randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced renal cell carcinoma (RCC): Results from the part 2 placebo-controlled trial
Martin H. Voss, MD of Memorial Sloan Kettering outlines the DART Study: A phase 2 randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced renal cell carcinoma (RCC): Re...
Author: kidneycancer
Added: 11/07/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Study | Urology & Nephrology